Zynerba Reports Positive Top Line Results from Autism Study
Zynerba Pharmaceuticals Inc. (ZYNE) announced encouraging results from its Phase 2 BRIGHT trial. The study aimed to evaluate the safety, tolerability and efficacy of the drug candidate in pediatric and adolescent patients with autism spectrum disorder. The patients suffering from moderate-to-severe symptoms of ASD were given Zygel as an add-on therapy to their standard of care.
The study was a 14-week exploratory, open label Phase 2 trial and enrolled 37 patients at single clinical site. The enrolled patients ranged from three to 17 years